Physician profile
Misti Newson
NPI 1295400422
$55,594.35
in general payments reported to CMS, 2019-2025
17 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $744 · 2023: $1,797 · 2024: $6,837 · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $11K · Food and Beverage: $9,377 · Consulting Fee: $3,697 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $15,356.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,930.00 |
| Travel and Lodging | $11,029.52 |
| Food and Beverage | $9,376.63 |
| Consulting Fee | $3,697.37 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28,964.35 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $19,230.93 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $1,253.56 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,208.18 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,185.18 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $815.68 | 2022-2025 | |
| Alkermes, INC. | $750.36 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $617.98 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $557.96 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Scientific Affairs, LLC | $248.64 | 2024-2025 | Invega Sustenna |
| Corium, LLC | $219.77 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.97 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $140.62 | 2024 | Qelbree |
| Indivior INC. | $63.69 | 2023-2024 | Perseris |
| Lundbeck LLC | $49.29 | 2023-2024 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.20 | 2021-2025 | Entyvio, Trintellix |
| Sunovion Pharmaceuticals INC. | $25.99 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misti Newson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.